Prof Karim Fizazi, MD, PhD

In by OncAcadAdminDFML

Gustave Roussy and the University of Paris-Saclay, Villejuif, France

Prof. Fizazi is a Medical Oncologist at Institute Gustave Roussy, and Professor of Oncology at the University of Paris-Saclay, Villejuif, France. He was head of department of Cancer Medicine at Institute Gustave Roussy from 2005 to 2018 and became Professor at the University of Paris, France in 2009. He is the president of the French Groupe d’Etude des Tumeurs Genito-Urinaires (GETUG).

Prof. Fizazi trained as a medical student at the University of Poitiers, France, before completing his residency (Internat) in Paris. In 1997, he completed a fellowship in medical oncology at Gustave Roussy. After a visiting professorship at the MD Anderson Cancer Center in Houston, TX, USA from 1999 to 2001 where he was working on preclinical models of bone metastases from prostate cancer, he gained his PhD in Molecular Oncology in 2003.

Prof. Fizazi established the Prostate Cancer Consortium in Europe (PEACE) in 2013, to push forward clinical research for prostate cancer in Europe. He is currently leading several large PEACE European academic phase III trials: PEACE-1, PEACE-2 (testing cabazitaxel and pelvic radiotherapy in very high-risk localised prostate cancer, which has completed a 750-patient accrual), and the ongoing PEACE-4 trial, which is testing the role of aspirin and statins in castrate-resistant prostate cancer. The PEACE-6 platform of phase 3 trials aims to test different hypotheses in different subgroups of men with M1 prostate cancer. To date, Prof. Fizazi has chaired six practice-changing trials in the field of genitourinary oncology, including the pivotal denosumab 103 trial, the GETUG 13 trial, the LATITUDE trial, and the TRITON-3 trial.

He is Associate Editor of the European Journal of Cancer. Furthermore, he has authored numerous abstracts at international congresses and has published more than 450 peer-reviewed articles.